JANUVIA
In the US, JANUVIA (sitagliptin systemic) is a member of the drug class dipeptidyl peptidase 4 inhibitors and is used to treat Diabetes, Type 2.
US matches:
UK matches:
Ingredient matches for JANUVIA
Sitagliptin is reported as an ingredient of JANUVIA in the following countries:
- Denmark
- Hong Kong
- Peru
- Romania
- Slovenia
- Turkey
Sitagliptin phosphate (a derivative of Sitagliptin) is reported as an ingredient of JANUVIA in the following countries:
- Canada
- Malaysia
- Singapore
- Taiwan
- Thailand
Sitagliptin phosphate hydrate (a derivative of Sitagliptin) is reported as an ingredient of JANUVIA in the following countries:
- Aruba
- Australia
- Austria
- Bahamas
- Bahrain
- Barbados
- Belgium
- Brazil
- Cayman Islands
- Chile
- China
- Costa Rica
- Croatia (Hrvatska)
- Czech Republic
- Dominican Republic
- El Salvador
- Finland
- France
- Georgia
- Germany
- Greece
- Guatemala
- Honduras
- Iceland
- Ireland
- Israel
- Italy
- Jamaica
- Latvia
- Lithuania
- Mexico
- Netherlands
- New Zealand
- Nicaragua
- Norway
- Philippines
- Poland
- Portugal
- Puerto Rico
- Serbia
- South Korea
- Spain
- Sweden
- Switzerland
- Trinidad & Tobago
- United Kingdom
- United States
International Drug Name Search
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
